Filing Flows › TScan Therapeutics (TCRX) › Recalls, complaints & regulation
TScan Therapeutics (TCRX): clinical trials
TScan Therapeutics (TCRX) beyond its filings: 5 active clinical trials.
TScan Therapeutics' latest quarter
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does TScan Therapeutics have?
5 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.